Jefferies raised the firm’s price target on Insulet (PODD) to $400 from $375 and keeps a Buy rating on the shares. The company reported a quarterly beat with health trends in T2, with total sales outperforming within and outside the U.S., the analyst tells investors in a research note. The firm is encouraged by the results, momentum in new customer starts, and the T2 pickup, and views Q4 guidance as conservative.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet’s Strong Financial Performance and Growth Prospects Earn Buy Rating from Analyst
- Insulet’s Strong Q3 Performance and International Expansion Drive Buy Rating
- Insulet sees Q4 revenue growth 25%-28% from $597.5M last year, consensus $729.9M
- Insulet raises FY25 revenue growth view to 28%-29% from 24%-27%
- Insulet reports Q3 adjusted EPS $1.24, consensus $1.15